Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats

J Hepatol. 2004 Feb;40(2):234-8. doi: 10.1016/j.jhep.2003.10.010.

Abstract

Background/aims: Nitric oxide (NO), a potent vasodilator, plays a significant role in the vascular hyposensitivity to vasoconstrictors related to portal hypertension. Chronic NO inhibition ameliorates portal-systemic collaterals in portal hypertensive rats. This study investigated whether chronic NO inhibition by NG-nitro-L-arginine methyl ester (L-NAME) improves the portal-systemic collateral vascular responsiveness to arginine vasopressin (AVP) in portal hypertensive rats.

Methods: Partially portal vein-ligated (PVL) rats received L-NAME in tap water (approximately 25 mg/kg per day) or tap water only (control) since 2 days prior to until 7 days after PVL. Mean arterial pressure was measured on the 8th day. By in situ perfusion model, different concentrations of AVP (10(-10)-10(-7) M) with a constant flow rate (20 ml/min) were applied to assess the perfusion pressure of collateral vessels. In another series, perfusion with different flow rates (5-30 ml/min) was used to obtain flow-pressure curves: the slopes represent collateral vascular resistances and higher resistances indicate less collaterals.

Results: Mean arterial pressure was higher in the L-NAME-treated group than that of the control group (P<0.05). As compared with the controls, L-NAME-treated rats achieved significantly higher perfusion pressures in response to AVP. In addition, chronic L-NAME treatment also induced an increase of collateral vascular resistance, suggesting the attenuation of portal-systemic shunting.

Conclusions: Chronic NO inhibition ameliorates portal-systemic shunting and improves the collateral vascular responsiveness to AVP in portal hypertensive rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine Vasopressin / metabolism
  • Blood Pressure / drug effects
  • Collateral Circulation / physiology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Hypertension, Portal / drug therapy*
  • Hypertension, Portal / metabolism
  • Hypertension, Portal / physiopathology*
  • Ligation
  • Liver Circulation / drug effects
  • Liver Circulation / physiology
  • Male
  • NG-Nitroarginine Methyl Ester / pharmacology*
  • Nitric Oxide / metabolism*
  • Portal Vein
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Enzyme Inhibitors
  • Arginine Vasopressin
  • Nitric Oxide
  • NG-Nitroarginine Methyl Ester